Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more
Windtree Therapeutics Inc - Asset Resilience Ratio
Windtree Therapeutics Inc (WINT) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2019)
This chart shows how Windtree Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Windtree Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Windtree Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Windtree Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Windtree Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Windtree Therapeutics Inc (1996–2019)
The table below shows the annual Asset Resilience Ratio data for Windtree Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $118.97 Million | -- |
| 2018-12-31 | 11.69% | $13.96 Million | $119.40 Million | +5.46pp |
| 2008-12-31 | 6.23% | $2.05 Million | $32.89 Million | -19.40pp |
| 2007-12-31 | 25.62% | $16.08 Million | $62.74 Million | +23.21pp |
| 2006-12-31 | 2.41% | $829.00K | $34.40 Million | -3.39pp |
| 2005-12-31 | 5.80% | $3.25 Million | $56.01 Million | -1.49pp |
| 2004-12-31 | 7.29% | $2.74 Million | $37.64 Million | -43.28pp |
| 2002-12-31 | 50.57% | $10.65 Million | $21.06 Million | -13.91pp |
| 2001-12-31 | 64.48% | $12.94 Million | $20.07 Million | +5.71pp |
| 2000-12-31 | 58.77% | $11.59 Million | $19.72 Million | +4.79pp |
| 1999-12-31 | 53.97% | $2.50 Million | $4.63 Million | -0.38pp |
| 1998-12-31 | 54.35% | $2.50 Million | $4.60 Million | +11.61pp |
| 1997-12-31 | 42.74% | $5.00 Million | $11.70 Million | -36.21pp |
| 1996-12-31 | 78.95% | $1.50 Million | $1.90 Million | -- |